Park Square Financial Group LLC Makes New $227,000 Investment in Axon Enterprise, Inc. (NASDAQ:AXON)

Park Square Financial Group LLC acquired a new position in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 382 shares of the biotechnology company's stock, valued at approximately $227,000.

Other hedge funds have also modified their holdings of the company. Mutual Advisors LLC bought a new position in Axon Enterprise in the 4th quarter valued at $333,000. Brighton Jones LLC bought a new position in shares of Axon Enterprise during the 4th quarter worth $480,000. Cornerstone Wealth Management LLC bought a new stake in Axon Enterprise during the fourth quarter valued at about $260,000. Geneos Wealth Management Inc. boosted its position in Axon Enterprise by 630.0% during the fourth quarter. Geneos Wealth Management Inc. now owns 1,847 shares of the biotechnology company's stock valued at $1,098,000 after purchasing an additional 1,594 shares in the last quarter. Finally, Linden Thomas Advisory Services LLC boosted its position in Axon Enterprise by 20.5% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 910 shares of the biotechnology company's stock valued at $541,000 after purchasing an additional 155 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on AXON. Needham & Company LLC increased their price target on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. JMP Securities reiterated an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. Barclays raised their price objective on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. The Goldman Sachs Group raised their price objective on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Finally, Craig Hallum lowered Axon Enterprise from a "buy" rating to a "cautious" rating in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the stock. According to MarketBeat, Axon Enterprise currently has a consensus rating of "Moderate Buy" and an average price target of $652.73.

Axon Enterprise Price Performance

Shares of Axon Enterprise stock traded up $4.92 on Wednesday, reaching $751.00. The company's stock had a trading volume of 524,465 shares, compared to its average volume of 739,108. The company has a market capitalization of $58.47 billion, a P/E ratio of 194.06, a PEG ratio of 5.17 and a beta of 1.24. Axon Enterprise, Inc. has a 52-week low of $273.52 and a 52-week high of $755.05. The stock has a 50-day moving average price of $614.09 and a 200-day moving average price of $608.69. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. The business had revenue of $603.63 million during the quarter, compared to analysts' expectations of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The business's revenue was up 31.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.15 earnings per share. Analysts expect that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Insider Transactions at Axon Enterprise

In other news, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $540.99, for a total value of $5,409,900.00. Following the sale, the chief executive officer now directly owns 3,063,982 shares of the company's stock, valued at $1,657,583,622.18. The trade was a 0.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Brittany Bagley sold 3,400 shares of Axon Enterprise stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $700.00, for a total value of $2,380,000.00. Following the completion of the sale, the chief financial officer now directly owns 131,833 shares in the company, valued at $92,283,100. This represents a 2.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 34,969 shares of company stock valued at $23,127,314 over the last ninety days. Insiders own 5.70% of the company's stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.